GSK 2634673F

Drug Profile

GSK 2634673F

Alternative Names: 18F-FBA-A20FMDV2; GSK263467F

Latest Information Update: 09 Feb 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Imaging agents; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Idiopathic pulmonary fibrosis

Most Recent Events

  • 14 Dec 2015 Queen Mary University of London plans a phase I trial in Solid tumours (Diagnosis) in United Kingdom
  • 07 Feb 2014 Phase-I clinical trials in Idiopathic pulmonary fibrosis (Diagnosis) in United Kingdom (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top